Capital expenditure

Delivering quality therapy through generations

Printable version

Investments	Capital expenditure Capital expenditure combined with intangible assets in 2008 totalled HUF 22,010 million (EUR 87.6 million), compared to HUF 23,197 million (EUR 92.3 million) reported for 2007. Responing to the adverse business environment in Hungary, Richter has deliberately reduced capital expenditure in 2007 and 2008 nevertheless not compromising its high manufacturing standards. In line with the above important equipment replacements occurred at the injectables plant and at the tabletting facilities in Budapest.
In 2007 we obtained most of the necessary regulatory approvals required for long term manufacturing in that location. Recently new homogenisers and granulators were put into operation at our tabletting facility in Budapest and our injectable plant was also extended with a new lyophilizing and filling equipment. The new chemical research centre was completed in early 2007 with workplaces being occupied by late March without compromising activities performed. R&D investments

QUICKLINKS